יוקריאס 50/850 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

METFORMIN HYDROCHLORIDE 850 MG; VILDAGLIPTIN 50 MG

Commercializzato da:

NOVARTIS PHARMA SERVICES AG

Codice ATC:

A10BA02

Forma farmaceutica:

FILM COATED TABLETS

Via di somministrazione:

PER OS

Prodotto da:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Gruppo terapeutico:

METFORMIN

Indicazioni terapeutiche:

Eucreas is indicated in the treatment of type 2 diabetes mellitus:• Eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• Eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• Eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

Data dell'autorizzazione:

2010-07-01